A New Era in CLL and SLL Treatment: FDA Approval of Acalabrutinib + Venetoclax (2026)
In this article
A New Era in CLL and SLL Treatment: The Acalabrutinib and Venetoclax Combination
The FDA has approved a new chemotherapy-free, fixed-duration treatment regimen for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Scope of Approval and the New Standard
On 7 February 2026, the FDA approved the combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- A Chemotherapy-Free Option: The synergistic use of two targeted agents.
- Fixed-Duration Treatment: Treatment completed according to a defined schedule rather than continued indefinitely.
- High Efficacy: Superior progression-free survival compared with standard chemoimmunotherapy.
The AMPLIFY Study: Clinical Data
This approval is based on the phase III AMPLIFY study involving 520 patients. Patients were randomized to acalabrutinib + venetoclax or standard chemoimmunotherapy (FCR or Obinutuzumab + Chlorambucil).
82% Reduction
Risk of Disease Progression
%90+
Combination Arm
Recommended Treatment Schedule
Treatment begins with acalabrutinib and then continues with the addition of venetoclax. This approach aims to minimize the risk of tumor lysis syndrome (TLS).
| Drug | Administration | Timing |
|---|---|---|
| Acalabrutinib | 100 mg twice daily | From cycle 1 |
| Venetoclax | Weekly dose escalation (Ramp-up) | Added in cycle 4 |
| Total Duration | Usually 12 cycles (Approximately 1 year) | |
The shift from "indefinite treatment" to "fixed-duration treatment" in CLL is revolutionary for patients' quality of life. The combination of Acalabrutinib and Venetoclax produces deep molecular responses by targeting two different biological pathways (BTK and BCL-2) simultaneously.
This approval offers the possibility of long-term remission without the need for chemotherapy, especially for patients with high-risk genetic features.
References
- FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma. February 2026.
- AMPLIFY (NCT03836261) Clinical Trial Results.
- Calquence (acalabrutinib) Prescribing Information.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.